מדיטבין 200 מ"ג

Pays: Israël

Langue: hébreu

Source: Ministry of Health

Ingrédients actifs:

GEMCITABINE AS HYDROCHLORIDE 200 MG/VIAL

Disponible depuis:

MEDISON PHARMA LTD

Code ATC:

L01BC05

forme pharmaceutique:

POWDER FOR SOLUTION FOR INFUSION

Mode d'administration:

I.V

Fabriqué par:

INTAS PHARMACEUTICALS LTD, INDIA

Groupe thérapeutique:

GEMCITABINE

indications thérapeutiques:

Palliative treatment of patients with locally advanced or metastatic non-small cell lung cancer and locally advanced or metastatic adenocarcinoma of the pancreas and for patients with 5-FU refractory pancreatic cancer. Gemcitabine is indicated for the treatment of patients with bladder cancer at the invasive stage. Breast cancer: Gemcitabine in combination with paclitaxel is indicated for the treatment of patients with unresectable locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. Prior chemotherapy should have included an anthracycline unless clinically contraindicated. Ovarian cancer: Gemcitabine in combination with carboplatin is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma whom have relapsed at least six months after platinum - based therapy.

Date de l'autorisation:

2012-11-01